Skip to main content

Day: November 16, 2025

FLSmidth announces changes to the Executive Leadership Team; CEO Mikko Keto stepping down and leaving FLSmidth

COMPANY ANNOUNCEMENT NO. 44-2025 FLSmidth & Co. A/S 16 November 2025 Copenhagen, Denmark   FLSmidth & Co. A/S (FLSmidth) today announces that Chief Executive Officer, Mikko Keto, has informed the Board of Directors of his decision to step down from his position to assume an executive role with a non-competing company. Mikko Keto will continue in his current capacity in the coming months to ensure business continuity, while the Board of Directors advances a structured CEO succession process. It is expected that Mikko Keto will leave the company during H1 2026. The Board of Directors of FLSmidth has a well-prepared succession plan in place, and the search for Mikko Keto’s successor starts immediately. The Board of Directors will announce the appointment of a successor once the process has been concluded. Mikko Keto joined FLSmidth...

Continue reading

Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy

Shareholders approved all proposals, confirming Faraday Future Intelligent Electric Inc. (“Faraday Future”) as the Company’s new majority and controlling shareholder. Faraday Future will nominate a majority of board seats prior to November 20 as part of the Company’s strategic transformation. The Company will host an official renaming and ticker activation ceremony at Nasdaq Headquarters in New York on November 20, adopting the new ticker symbol AIXC. During the ceremony, the Company will unveil a new business model, ecosystem structure, and three-year development roadmap positioning AIxCrypto as a leading gateway to the AI × Web3 era. The transition introduces cross-ecosystem enablement between the two companies.Carlsbad, CA, Nov. 16, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”)...

Continue reading

2025 Illuminations of the Champs-Elysées – JCDecaux supports Swarovski in its partnership with the Comité Champs-Elysées

2025 Illuminations of the Champs-Elysées – JCDecaux supports Swarovski in its partnership with the Comité Champs-Elysées  Paris, November 16th, 2025 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announces that JCDecaux France is supporting Swarovski in its partnership with the Comité Champs-Elysées for the 2025 Illuminations. Swarovski is supporting the Comité Champs-Elysées as the exclusive partner of Holiday Season illuminations of the most beautiful avenue in the world, whose godmother this year will be Léa SEYDOUX. JCDecaux, which has been a partner of the Comité since 2014 to identify and activate the prestigious brands involved in the creation of the Illuminations, is collaborating with Swarovski, Master of Light since 1895, in this new magical operation on the most beautiful avenue...

Continue reading

Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting

Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) — Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD), today announced new data shared at the recent American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place November 13–16, 2025, in Chicago, Illinois. Pivotal FDA Study Comparison of Two Hyaluronic Acid Fillers for Midface Augmentation and Associated Improvement in Nasolabial Folds Appearance led to Obagi Hyaluronic Acid Featured as a Top 10 Abstract Presented by Dr. Sue Ellen Cox: “As an investigator in this pivotal study, I was pleased that the data was recognized as one of the top 10 abstracts and selected for an oral presentation,” commented...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.